Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.30) by 106.67 percent. This is a 33.33 percent increase over losses of $(0.93) per share from the same period last year. The company reported quarterly sales of $3.752 million which missed the analyst consensus estimate of $3.796 million by 1.16 percent. This is a 47.08 percent increase over sales of $2.551 million the same period last year.